GILLIS STEVEN

CIK 000122959221 companiesSEATTLE, WA

SEC Profile

Transactions

Companies

Filings

CIK

0001229592

Recent Transactions

50 trades

Disposition to Issuer
Metsera, Inc.$MTSR
Common Stock
2025-11-13−18,503,128→ 0 total
Disposition to Issuer
Metsera, Inc.$MTSR
Common Stock
2025-11-13−8,313,680→ 0 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2025-10-27$2.61/sh+1,915,700→ 6,046,907 total
Purchase
Prime Medicine, Inc.$PRME
Common Stock
2025-08-01$3.30/sh+3,030,300→ 6,230,300 total
Conversion
Metsera, Inc.$MTSR
Series Seed Preferred Stock
2025-02-03−19,933,333→ 0 total
Conversion
Metsera, Inc.$MTSR
Series B Convertible Preferred Stock
2025-02-03−2,678,571→ 0 total
Purchase
Metsera, Inc.$MTSR
Common Stock
2025-02-03$18.00/sh+789,998→ 8,313,680 total
Purchase
Metsera, Inc.$MTSR
Common Stock
2025-02-03$18.00/sh+1,432,224→ 18,503,128 total
Conversion
Metsera, Inc.$MTSR
Common Stock
2025-02-03+7,523,682→ 7,523,682 total
Conversion
Metsera, Inc.$MTSR
Common Stock
2025-02-03+16,006,949→ 17,070,904 total
Conversion
Metsera, Inc.$MTSR
Series A Convertible Preferred Stock
2025-02-03−15,000,000→ 0 total
Conversion
Metsera, Inc.$MTSR
Series A Convertible Preferred Stock
2025-02-03−15,000,000→ 0 total
Conversion
Metsera, Inc.$MTSR
Series B Convertible Preferred Stock
2025-02-03−2,678,571→ 0 total
Conversion
Rapport Therapeutics, Inc.$RAPP
Series A Preferred Stock
2024-06-10−20,000,000→ 0 total
Conversion
Rapport Therapeutics, Inc.$RAPP
Common Stock
2024-06-10+3,728,738→ 3,728,738 total
Conversion
Rapport Therapeutics, Inc.$RAPP
Series B Preferred Stock
2024-06-10−11,924,138→ 0 total
Conversion
Boundless Bio, Inc.$BOLD
Common Stock
2024-04-02+1,048,433→ 1,048,433 total
Conversion
Boundless Bio, Inc.$BOLD
Common Stock
2024-04-02+589,743→ 617,092 total
Purchase
Boundless Bio, Inc.$BOLD
Common Stock
2024-04-02$16.00/sh+66,667→ 683,759 total
Conversion
Boundless Bio, Inc.$BOLD
Series A Convertible Preferred Stock
2024-04-02−424,908→ 0 total
Conversion
Boundless Bio, Inc.$BOLD
Series B Convertible Preferred Stock
2024-04-02−227,920→ 0 total
Conversion
Boundless Bio, Inc.$BOLD
Common Stock
2024-04-02+787,545→ 828,570 total
Conversion
Boundless Bio, Inc.$BOLD
Series A Convertible Preferred Stock
2024-04-02−454,212→ 0 total
Conversion
Boundless Bio, Inc.$BOLD
Series C Convertible Preferred Stock
2024-04-02−164,835→ 0 total
Conversion
Boundless Bio, Inc.$BOLD
Series C Convertible Preferred Stock
2024-04-02−201,465→ 0 total
Conversion
Boundless Bio, Inc.$BOLD
Series C Convertible Preferred Stock
2024-04-02−366,301→ 0 total
Purchase
Boundless Bio, Inc.$BOLD
Common Stock
2024-04-02$16.00/sh+133,333→ 1,181,766 total
Conversion
Boundless Bio, Inc.$BOLD
Series A Convertible Preferred Stock
2024-04-02−586,080→ 0 total
Purchase
Prime Medicine, Inc.$PRME
Common Stock
2024-02-15$6.25/sh+3,200,000→ 3,200,000 total
Purchase
Sana Biotechnology, Inc.$SANA
Common Stock
2024-02-08$5.50/sh+727,272→ 12,446,022 total
Purchase
Sana Biotechnology, Inc.$SANA
Common Stock
2024-02-08$5.50/sh+727,272→ 12,446,022 total
Purchase
Sana Biotechnology, Inc.$SANA
Common Stock
2024-02-08$5.50/sh+363,637→ 10,667,387 total
Other
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-12-08+703,061→ 1,387,228 total
Other
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-12-08+1,176,593→ 2,321,566 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-11-14$11.98/sh+3,357→ 4,131,207 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-11-13$11.75/sh+31,653→ 4,127,850 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-11-10$11.75/sh+5,431→ 4,096,197 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-11-10$11.37/sh+11,844→ 4,090,766 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-11-09$10.53/sh+31,079→ 4,078,922 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-11-08$10.78/sh+69,127→ 4,024,719 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-11-08$11.79/sh+23,124→ 4,047,843 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-11-07$11.50/sh+30,192→ 3,955,592 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-11-06$11.55/sh+43,082→ 3,925,400 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-11-03$11.38/sh+22,420→ 3,882,318 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-09-29$13.98/sh+34,560→ 3,859,898 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-09-28$13.69/sh+25,110→ 3,825,338 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-09-28$13.06/sh+16,841→ 3,800,228 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-09-27$12.31/sh+24,504→ 3,783,387 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-09-26$11.73/sh+34,000→ 3,758,883 total
Purchase
Neumora Therapeutics, Inc.$NMRA
Common Stock
2023-09-25$10.80/sh+30,773→ 3,694,916 total

Recent Filings

Address

ARCH VENTURE PARTNERS 1000 2ND AVENUE, SUITE 3700

SEATTLE, WA, 98104

View on SEC.gov